1
|
Aluai-Cunha C, Matos A, Amorim I, Carvalho F, Rêma A, Santos A. Immunohistochemical Expression of Platelet-Derived Growth Factor Receptor β (PDGFR-β) in Canine Cutaneous Peripheral Nerve Sheath Tumors: A Preliminary Study. Vet Sci 2022; 9:vetsci9070345. [PMID: 35878362 PMCID: PMC9319676 DOI: 10.3390/vetsci9070345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2022] [Revised: 06/30/2022] [Accepted: 07/07/2022] [Indexed: 11/29/2022] Open
Abstract
Simple Summary The peripheral nerve sheath tumors are relatively common neoplasms, belong to the soft tissue sarcomas group, and are poorly investigated in veterinary medicine; the diagnosis is complex, and therapeutic options are limited. The platelet-derived growth factor receptors, namely the β subunit, are an important class of tyrosine kinase receptors that can be activated by genetic alterations and contribute to the process of carcinogenesis, so the inhibition of this receptor is an important therapeutic target. Using the immunohistochemical technique, this study aims to evaluate the expression of this receptor in 19 samples, 10 malignant and 9 benign tumors. The results showed that the majority of benign tumors, about 67% of cases, expressed the receptor in less than 25% of neoplastic cells and, in 80% cases of malignant tumors, the receptor was expressed in more than 25% of neoplastic cells. It was also found that, in the larger tumors, the expression of this receptor was significantly higher. With these findings it seems reasonable to speculate that the drugs able to inhibit this receptor, such as toceranib, may be considered in the therapeutic approach of these tumors. Abstract As in humans, the prevalence of tumors in companion animals is increasing dramatically and there is a strong need for research on new pharmacological agents particularly for the treatment of those tumors that are resistant to conventional chemotherapy agents such as soft tissue sarcomas (STS). Because malignant (MPNST) and benign peripheral nerve sheath tumors (BPNST) are relatively common STS in dogs, the aim of this retrospective study was to evaluate the immunohistochemical (IHC) expression of PDGFR-β, contributing to its characterization as a potential target for their treatment. A total of 19 samples were included, 9 histologically classified as benign and the other 10 as malignant. The results showed diffuse immunoexpression in the cytoplasm of neoplastic cells. Six (66.7%) BPNST expressed the receptor in less than 25% of neoplastic cells and only three (33.3%) exhibited labelling in more than 25% of neoplastic cells. In contrast, all MPNST expressed PDGFR-β, and in 8 (80%) of these samples, the receptor was expressed in more than 25% of neoplastic cells, and only 2 (20%) cases expressed the receptor in less than 25% of neoplastic cells. PDGFR-β expression was significantly higher in MPNST and larger tumors, suggesting that drugs able to inhibit the activity of this tyrosine kinase receptor, such as toceranib, may be considered in the approach of unresectable tumors and/or in the context of adjuvant or neoadjuvant therapies.
Collapse
Affiliation(s)
- Catarina Aluai-Cunha
- Department of Veterinary Clinics, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, R. Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal; (C.A.-C.); (A.M.)
| | - Augusto Matos
- Department of Veterinary Clinics, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, R. Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal; (C.A.-C.); (A.M.)
- Animal Science and Study Centre (CECA), Food and Agrarian Sciences and Technologies Institute (ICETA), P. Gomes Teixeira, Apartado 55142, 4051-401 Porto, Portugal
| | - Irina Amorim
- Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, R. Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal; (I.A.); (F.C.); (A.R.)
- Institute of Molecular Pathology and Immunology (IPATIMUP), University of Porto, R. Júlio Amaral de Carvalho 45, 4200-135 Porto, Portugal
- Institute for Research and Innovation in Health (I3S), University of Porto, R. Alfredo Allen 208, 4200-135 Porto, Portugal
| | - Fátima Carvalho
- Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, R. Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal; (I.A.); (F.C.); (A.R.)
| | - Alexandra Rêma
- Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, R. Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal; (I.A.); (F.C.); (A.R.)
| | - Andreia Santos
- Department of Veterinary Clinics, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, R. Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal; (C.A.-C.); (A.M.)
- Animal Science and Study Centre (CECA), Food and Agrarian Sciences and Technologies Institute (ICETA), P. Gomes Teixeira, Apartado 55142, 4051-401 Porto, Portugal
- Correspondence:
| |
Collapse
|
2
|
Avallone G, Muscatello LV, Leoni A, Roccabianca P, Lepri E, Crippa L, Bacci B. p53 Expression in Canine Liposarcoma Correlates With Myxoid Variant and Higher Proliferative Activity. Vet Pathol 2020; 57:620-622. [PMID: 32744152 DOI: 10.1177/0300985820941501] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Canine liposarcoma is classified as well differentiated (WDL), dedifferentiated (DDL), myxoid (ML), and pleomorphic (PL). Overexpression of the protooncogene MDM2 has been reported in WDL and DDL, but little is known regarding the role of p53 in their tumorigenesis. The aim of this study was to assess p53 expression in canine liposarcoma and compare it with subtype, grade, mitotic count (MC), Ki67 labeling index (LI), and MDM2 expression. Forty-seven cases were included (13 WDL, 3 DDL, 7 ML, and 24 PL); 17 were MDM2-positive (13 WDL, 3DDL, and 1ML). Five were p53-positive (4 ML and 1 WDL) but DDL and PL were consistently negative. p53 expression correlated with higher Ki67-LI, higher MC, and myxoid histotype. No correlation was found with grade and MDM2 expression. Based on these results canine liposarcoma seems to embody a group of neoplasms whose subtypes, especially ML, may represent distinct diseases rather than morphological variants of the same entity.
Collapse
|
3
|
Regan D, Garcia K, Thamm D. Clinical, Pathological, and Ethical Considerations for the Conduct of Clinical Trials in Dogs with Naturally Occurring Cancer: A Comparative Approach to Accelerate Translational Drug Development. ILAR J 2019; 59:99-110. [PMID: 30668709 DOI: 10.1093/ilar/ily019] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2017] [Revised: 11/26/2018] [Indexed: 01/21/2023] Open
Abstract
The role of comparative oncology in translational research is receiving increasing attention from drug developers and the greater biomedical research community. Pet dogs with spontaneous cancer are important and underutilized translational models, owing to dogs' large size and relative outbreeding, combined with their high incidence of certain tumor histotypes with significant biological, genetic, and histological similarities to their human tumor counterparts. Dogs with spontaneous tumors naturally develop therapy resistance and spontaneous metastasis, all in the context of an intact immune system. These fundamental features of cancer biology are often lacking in induced or genetically engineered preclinical tumor models and likely contribute to their poor predictive value and the associated overall high failure rate in oncology drug development. Thus, the conduct of clinical trials in pet dogs with naturally occurring cancer represents a viable surrogate and valuable intermediary step that should be increasingly incorporated into the cancer drug discovery and development pipeline. The development of molecular-targeted therapies has resulted in an expanded role of the pathologist in human oncology trials, and similarly the expertise of veterinary pathologists will be increasingly valuable to all phases of comparative oncology trial design and conduct. In this review, we provide a framework of clinical, ethical, and pathology-focused considerations for the increasing integration of translational research investigations in dogs with spontaneous cancer as a means to accelerate clinical cancer discovery and drug development.
Collapse
Affiliation(s)
- Daniel Regan
- Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado
| | - Kelly Garcia
- Biologic Resources Laboratory, University of Illinois, Chicago, Illinois
| | - Douglas Thamm
- Flint Animal Cancer Center, Colorado State University, Fort Collins, Colorado
| |
Collapse
|
4
|
Caswell JL, Bassel LL, Rothenburger JL, Gröne A, Sargeant JM, Beck AP, Ekman S, Gibson-Corley KN, Kuiken T, LaDouceur EEB, Meyerholz DK, Origgi FC, Posthaus H, Priestnall SL, Ressel L, Sharkey L, Teixeira LBC, Uchida K, Ward JM, Webster JD, Yamate J. Observational Study Design in Veterinary Pathology, Part 1: Study Design. Vet Pathol 2018; 55:607-621. [PMID: 30071806 DOI: 10.1177/0300985818785705] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Observational studies are the basis for much of our knowledge of veterinary pathology and are highly relevant to the daily practice of pathology. However, recommendations for conducting pathology-based observational studies are not readily available. In part 1 of this series, we offer advice on planning and conducting an observational study with examples from the veterinary pathology literature. Investigators should recognize the importance of creativity, insight, and innovation in devising studies that solve problems and fill important gaps in knowledge. Studies should focus on specific and testable hypotheses, questions, or objectives. The methodology is developed to support these goals. We consider the merits and limitations of different types of analytic and descriptive studies, as well as of prospective vs retrospective enrollment. Investigators should define clear inclusion and exclusion criteria and select adequate numbers of study subjects, including careful selection of the most appropriate controls. Studies of causality must consider the temporal relationships between variables and the advantages of measuring incident cases rather than prevalent cases. Investigators must consider unique aspects of studies based on archived laboratory case material and take particular care to consider and mitigate the potential for selection bias and information bias. We close by discussing approaches to adding value and impact to observational studies. Part 2 of the series focuses on methodology and validation of methods.
Collapse
Affiliation(s)
- Jeff L Caswell
- 1 Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada
| | - Laura L Bassel
- 1 Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada
| | - Jamie L Rothenburger
- 2 Department of Ecosystem and Public Health, Canadian Wildlife Health Cooperative, Faculty of Veterinary Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Andrea Gröne
- 3 Department of Pathobiology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
| | - Jan M Sargeant
- 4 Department of Population Medicine and Centre for Public Health and Zoonoses, University of Guelph, Guelph, Ontario, Canada
| | - Amanda P Beck
- 5 Albert Einstein College of Medicine, Bronx, NY, USA
| | - Stina Ekman
- 6 Department of Biomedicine and Veterinary Public Health, Swedish University of Agricultural Sciences, Uppsala, Sweden
| | - Katherine N Gibson-Corley
- 7 Department of Pathology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, USA
| | - Thijs Kuiken
- 8 Department of Viroscience, Erasmus University Medical Centre, Rotterdam, the Netherlands
| | | | - David K Meyerholz
- 10 University of Iowa Carver College of Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA
| | - Francesco C Origgi
- 11 Centre for Fish and Wildlife Health, Vetsuisse Faculty, University of Bern, Bern, Switzerland
| | - Horst Posthaus
- 12 Institute of Animal Pathology, Vetsuisse-Faculty, University of Bern, Bern, Switzerland
| | - Simon L Priestnall
- 13 Deparment Pathobiology & Population Sciences, The Royal Veterinary College, Hatfield, United Kingdom
| | - Lorenzo Ressel
- 14 Department of Veterinary Pathology and Public Health, Institute of Veterinary Science, University of Liverpool, Liverpool, United Kingdom
| | - Leslie Sharkey
- 15 Department of Clinical Sciences, Cummings School of Veterinary Medicine, Tufts University, N. Grafton, MA, USA
| | - Leandro B C Teixeira
- 16 Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, WI, USA
| | - Kazuyuki Uchida
- 17 Department of Veterinary Pathology, University of Tokyo, Tokyo, Japan
| | | | | | - Jyoji Yamate
- 20 Laboratory of Veterinary Pathology, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Izumisano City, Osaka, Japan
| |
Collapse
|
5
|
Walters L, Martin O, Price J, Sula MM. Expression of receptor tyrosine kinase targets PDGFR-β, VEGFR2 and KIT in canine transitional cell carcinoma. Vet Comp Oncol 2017; 16:E117-E122. [PMID: 28884928 DOI: 10.1111/vco.12344] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2017] [Revised: 07/10/2017] [Accepted: 08/01/2017] [Indexed: 01/05/2023]
Abstract
Transitional cell carcinoma (TCC) is the most common neoplasia of the canine urinary tract. It tends to be locally invasive and has a moderate metastatic rate. Receptor tyrosine kinases (RTKs) play an important role in promoting cell growth, differentiation and regulation of cell function. RTK inhibitor toceranib phosphate has been used anecdotally to treat TCC. The goal of this study was to evaluate archived normal urinary bladder, TCC and cystitis bladder samples for expression of toceranib phosphate targets: VEGFR2, PDGFR-β and stem cell factor receptor (KIT). A significant number of TCC samples expressed PDGFR-β compared with cystitis and normal bladder samples (P<.0001). While all the tumour samples stained positively for VEGFR2, there was no significant difference between tumour, cystitis and normal bladder samples in intensity scores or staining distribution. Minimal positive staining for KIT was noted in the tumour samples. Based on this proof of target study, further investigation is warranted to determine clinical response of TCC to toceranib phosphate.
Collapse
Affiliation(s)
- L Walters
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee
| | - O Martin
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee
| | - J Price
- Knoxville School of Information Sciences, University of Tennessee, Knoxville, Tennessee
| | - M M Sula
- Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee
| |
Collapse
|
6
|
Patel RB, Li T, Liao Z, Jaldeepbhai JA, Perera HAPNV, Muthukuda SK, Dhirubhai DH, Singh V, Du X, Yang J. Recent translational research into targeted therapy for liposarcoma. Stem Cell Investig 2017; 4:21. [PMID: 28447036 DOI: 10.21037/sci.2017.02.09] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2016] [Accepted: 02/19/2017] [Indexed: 12/18/2022]
Abstract
Liposarcomas (LPS) are among the most common soft tissue sarcomas, originating from adipocytes. Treatment for LPS typically involves surgical resection and radiation therapy, while the use of conventional cytotoxic chemotherapy for unresectable or metastatic LPS remains controversial. This review summarizes the results of recent translational research and trials of novel therapies targeting various genetic and molecular aberrations in different subtypes of LPS. Genetic aberrations such as the 12q13-15 amplicon, genetic amplification of MDM2, CDK4, TOP2A, PTK7, and CHEK1, point mutations in CTNNB1, CDH1, FBXW7, and EPHA1, as the fusion of FUS-DDIT3/EWSR1-DDIT3 are involved in the pathogenesis LPS and represent potential therapeutic candidates. Tyrosine kinase inhibitors targeting MET, AXL, IGF1R, EGFR, VEGFR2, PDGFR-β and Aurora kinase are effective in certain types of LPS. Abnormalities in the PI3K/Akt signaling pathway deregulation of C/EBP-α and its partner PPAR-γ, and the interaction between calreticulin (CRT) and CD47 are also promising therapeutic targets. These promising new approaches may help to supplement existing treatments for LPS.
Collapse
Affiliation(s)
- Rashi Bharat Patel
- International Medical School, Tianjin Medical University, Tianjin 300061, China.,Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China
| | - Ting Li
- Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China.,National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China
| | - Zhichao Liao
- Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China.,National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China
| | - Jivani Aakash Jaldeepbhai
- International Medical School, Tianjin Medical University, Tianjin 300061, China.,Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China
| | - H A Pavanika N V Perera
- International Medical School, Tianjin Medical University, Tianjin 300061, China.,Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China
| | - Sujani Kaushalya Muthukuda
- International Medical School, Tianjin Medical University, Tianjin 300061, China.,Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China
| | - Dholiya Hardeep Dhirubhai
- International Medical School, Tianjin Medical University, Tianjin 300061, China.,Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China
| | - Vaibhav Singh
- International Medical School, Tianjin Medical University, Tianjin 300061, China.,Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China
| | - Xiaoling Du
- Department of Diagnostics, Tianjin Medical University, Tianjin 300061, China
| | - Jilong Yang
- International Medical School, Tianjin Medical University, Tianjin 300061, China.,Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China.,National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China
| |
Collapse
|